In the news release, D2M Biotherapeutics Announces First Patient
Dosed in A Phase 1 Study ... issued 18-Apr-2024 by D2M Biotherapeutics, Inc. over PR
Newswire, the headline was incorrectly separated by PR Newswire
into two parts. The corrected release (with headline intact)
follows:
D2M Biotherapeutics Announces First Patient Dosed in A Phase 1
Study Evaluating DM919, a Novel MICA/B Antibody for Treating
Patients with Advanced Solid Tumors
NATICK,
Mass., April 18, 2024 /PRNewswire/ -- D2M
Biotherapeutics, Inc. (D2M), a clinical stage biotech company
focused on developing innovative therapies in treating
Immunological-Inflammatory diseases and cancers,
today announced that the first patient had been dosed in a
phase 1, open-label, dose escalation and expansion study of DM919,
a novel monoclonal antibody targeting MICA/B to restore and promote
anti-tumor response by T and natural killer (NK) cells for the
treatment of advanced solid tumors.
This phase 1, first-in-human, multicenter, dose-escalation and
expansion trial (NCT06328673) will evaluate the safety,
tolerability, pharmacokinetics, pharmacodynamics and clinical
activity of DM919 alone and in combination with anti-PD1 therapy in
patients with advanced or metastatic solid tumors.
"The initiation of this clinical study represents a major
milestone for D2M," said Nan Bing,
MD., Ph.D., co-founder and CEO of D2M. "The MICA/B
targeted therapy is a novel modality in cancer treatment through
its unique mode-of-action by addressing MICA/B mediated immune
escape presented in many types of tumors. It also has
potential to bring effective treatment against certain tumors with
MHC-I low expression, which are typically resistant to the current
immune check inhibitor agents. We are thrilled to work with our
Principal Investigator, Dr. Shiraj
Sen at Next Oncology to assess DM919's safety and clinical
activities in this Ph1 study."
Dr. Sen commented "DM919 has unique biological properties to
potentially restore a patient's innate and adaptive immunity
against cancers. We are eager to investigate DM919 as a
monotherapy agent and in combination with anti-PD1 therapy".
About DM919
DM919 is a humanized MICA/B-specific IgG1 monoclonal antibody
designed to block the shedding of MICA and MICB proteins from
cancer cells. Highly expressed in cancer cells, MICA/B are
stress-induced ligands recognized by both innate and adaptive
immune cells via NKG2D receptors. Through shedding MICA/B, tumor
cells develop immune escape. DM919 restores and enhances
NKG2D-dependent activation of T and NK cells in the tumor
micro-environment, and therefore promotes anti-tumor activity in
cancer patients.
D2M Biotherapeutics have shown that DM919 prevents MICA/B
shedding, stabilizes surface MICA/B and presents shed MICA/B to
activate NKG2D on NK or T cells and mediates antibody-dependent
cytotoxicity (ADCC) of tumor cells. In preclinical studies,
DM919 has demonstrated significant antitumor activity as a single
agent in a variety of tumor models. Furthermore, substantial
synergistic anti-tumor effects have been demonstrated when DM919 is
combined with anti-PD1 agent.
About D2M Biotherapeutics, Inc.
D2M Biotherapeutics is a clinical stage biopharmaceutical
company focused on discovery and development of innovative
medicines to help patients with unmet medical needs in oncology and
autoimmune diseases. D2M is revolutionizing immunological-based
drug development empowered by our proprietary INGENUITI (INtegrated
GENetics and mUlti-omIcs for Target Identification) platform.
Through INGENUITI, we systematically identify novel disease targets
of significant value by deep mining integrated disease and
functional genomic data with the power of machine learning and
proprietary bioinformatics algorithms.
Anchored by INGENUITI, D2M has built a diversified pipeline of
drug assets based on novel targets with unique modes of action and
strong human genetics support. By focusing on the
high-confidence targets with either FIC or BIC potential, we strive
to apply our human genetics data-driven approach and bring
transformative medicines to patients in need. For more
information, please visit www.d2mbio.com.
Contact
info@d2mbio.com
D2M Biotherapeutics, Inc.
22 Strathmore Road,
Natick, MA 01760, USA
View original content to download
multimedia:https://www.prnewswire.com/news-releases/d2m-biotherapeutics-announces-first-patient-dosed-in-a-phase-1-study-evaluating-302120400.html
SOURCE D2M Biotherapeutics, Inc.